Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$3.6
EPS
$-2
Face value
--
Shares outstanding
42,891,400
CFO
$-255.77 Mln
EBITDA
$-339.60 Mln
Net Profit
$-332.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Repare Therapeutics (RPTX)
| 1.5 | 43.3 | 4.7 | -64.0 | -46.7 | -- | -- |
|
BSE Sensex*
| 5.1 | 7.2 | 8.3 | 12.7 | 15.9 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Repare Therapeutics (RPTX)
| -81.8 | -50.4 | -30.3 | -38.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Repare Therapeutics (RPTX)
|
1.3 | 56.0 | 53.5 | -84.7 | -172.3 | -46.6 | -- | 0.4 |
| 48.2 | 7,502.9 | 1,196.0 | 158.1 | 19.6 | 7.6 | 57.7 | 4.0 | |
| 99.5 | 6,297.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.4 | |
| 56.2 | 10,350.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 46.3 | 12,304.8 | 2,168.7 | 521.3 | 31.8 | 23.1 | 25.4 | 4.5 | |
| 49.0 | 8,204.1 | 1,084.3 | 485.4 | 43.3 | 103.8 | 17.7 | 16.8 | |
| 291.8 | 6,280.4 | 317.4 | -391.6 | -118.9 | -52.6 | -- | 8.8 | |
| 296.4 | 8,384.8 | 2,156.6 | 416.4 | 15.6 | 56.5 | 22.3 | 14.1 | |
| 23.7 | 9,289.5 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 120.3 | 11,755.2 | 2,412.6 | 305.8 | 20.5 | 11.6 | 40.3 | 4.6 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to... discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. Address: 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9 Read more
President, CEO & Director
Mr. Lloyd Mitchell Segal
President, CEO & Director
Mr. Lloyd Mitchell Segal
Headquarters
Montreal, QC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Repare Therapeutics Inc (RPTX) stood at $ 177 Mln as on 31-Dec-24
The share price of Repare Therapeutics Inc (RPTX) is $1.33 (NASDAQ) as of 15-May-2025 16:00 EDT. Repare Therapeutics Inc (RPTX) has given a return of -46.65% in the last 3 years.
Repare Therapeutics Inc (RPTX) has a market capitalisation of $ 56 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Repare Therapeutics Inc (RPTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Repare Therapeutics Inc (RPTX) and enter the required number of quantities and click on buy to purchase the shares of Repare Therapeutics Inc (RPTX).
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. Address: 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9
The CEO & director of Mr. Lloyd Mitchell Segal. is Repare Therapeutics Inc (RPTX), and CFO & Sr. VP is Mr. Lloyd Mitchell Segal.
There is no promoter pledging in Repare Therapeutics Inc (RPTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,098
|
|
|
1,086
|
|
|
1,077
|
|
|
1,006
|
|
|
864
|
|
|
787
|
|
|
756
|
|
|
680
|
|
|
658
|
| Repare Therapeutics Inc. (RPTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-46.63
|
|
Operating margin(%)
|
-178.48
|
|
Net Margin(%)
|
-158.37
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Repare Therapeutics Inc (RPTX) was $0 Mln.
$0.03
(
